EQS-News: Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
Issuer: Sernova Corp.
/ Key word(s): Conference/Research Update
LONDON, Ontario – April 10, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Barcelona in Barcelona, Spain and livestreamed globally. Panel: Navigating CGTx Development in 2023 Date: Wednesday, April 12, 2023 Time: 4:45 – 5:30 PM CET Location: BioCentriq Ballroom | Hotel Arts Barcelona, Spain Virtual attendance is available which includes a livestream of Sernova’s presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemed.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors. Investors should contact Laura Stringham at [email protected].
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress two additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT: Corporate: Investors: Corey Davis, Ph.D. Media: Elizabeth Miller, M.D.
FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Sernova Corp. |
700 Collip Circle, Ste 114 | |
N6G 4X8 London | |
Canada | |
Internet: | https://www.sernova.com/contact/ |
EQS News ID: | 1604219 |
End of News | EQS News Service |
|
Sernova Corp. Aktie
Die Sernova Corp. Aktie steht noch am Anfang: Zu wenige Einschätzungen für ein Sentiment.
Die Community sieht für Sernova Corp. ein Kursziel von 12 €, was den aktuellen Kurs von 0.19 € weit übersteigt.